Since metformin use has been shown to reduce Aβ deposition and abnormal tau phosphorylation, alleviate inflammation, increase insulin sensitivity, and enhance neurogenesis [342–345], all of which are key mechanisms of AD, the relationship between metformin use and AD risk warrants further investigation. This evidence concerns the gene MAPT and Alzheimer disease.